Vadastuximab disitamab vedotin antibody-drug conjugate representing a significant advancement in the approach of acute myeloid leukemia (AML). This pioneering therapy specifically targets CD33, a protein https://minayucg749401.blog5.net/92148696/vadastuximab-a-deep-examination-into-cd33-targeted-therapy